Revance Therapeutics Inc
NASDAQ:RVNC

Watchlist Manager
Revance Therapeutics Inc Logo
Revance Therapeutics Inc
NASDAQ:RVNC
Watchlist
Price: 3.65 USD Market Closed
Market Cap: 381m USD

Operating Margin
Revance Therapeutics Inc

-67.8%
Current
-210%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-67.8%
=
Operating Profit
-167.6m
/
Revenue
247m

Operating Margin Across Competitors

No Stocks Found

Revance Therapeutics Inc
Glance View

Market Cap
382.9m USD
Industry
Pharmaceuticals

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 495 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The firm is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. The company offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

RVNC Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-67.8%
=
Operating Profit
-167.6m
/
Revenue
247m
What is the Operating Margin of Revance Therapeutics Inc?

Based on Revance Therapeutics Inc's most recent financial statements, the company has Operating Margin of -67.8%.

Back to Top